adplus-dvertising
Connect with us

Investment

Chemistree Details Immunoflex Investment – Canada NewsWire

Published

 on


Cannabinoid-Linked, Immunology and Virology focused Biotech Venture

VANCOUVER, BC, June 18, 2020 /CNW/ – Chemistree Technology Inc. (CSE: CHM) (CSE: CHM.wt) (US OTCQB: CHMJF) (the “Company” or “Chemistree”), further to its announcement on June 15, 2020, the Company is pleased to introduce ImmunoFlex Therapeutics Inc. (“ImmunoFlex”) and provide a complete description of the investment per the Binding Letter of Intent.

ImmunoFlex is a team unified around a common goal of working with the immune system to prevent and combat disease. The first products are designed to improve the way the world prevents and treats viral infection. ImmunoFlex works to find solutions for people who want to enhance the preparedness of their immune function in defence and combat viral infection; preventing occurrences, and decreasing the severity of viral infections. By learning from the immune system, ImmunoFlex develops products that leverage existing compounds previously unknown ability to provide immune preparedness and resilience.

300x250x1

For the past three months, Chemistree has been regularly solicited with requests for funding by ventures proposing treatments or products related to the current pandemic, most of which lacked the team and development that ImmunoFlex displays. Chemistree’s management immediately recognized that the ImmunoFlex team had been working on immunological and virological therapeutics well before the outbreak of the global pandemic. It is this level of high-quality scientific research and logical product development in the field of immune system response that makes ImmunoFlex an important and timely investment.

Chemistree President Karl Kottmeier commented, “We are thrilled to be the primary seed investors into ImmunoFlex. The timeliness of the products under development, driven by the tremendous collective experience and successes of the ImmunoFlex management team makes this truly a compelling investment for Chemistree. It is rare for a small company like Chemistree to get a chance to provide funding to a start up like ImmunoFlex. The track record of Dr. Vernon Oi alone as one of Stanford University’s most prolific patent filers and royalty generators would normally place this out of reach for Chemistree. Fortunately, our positioning as a cannabis-focused investment company and ideal timing made this possible. I encourage shareholders and interested investors to go to www.immunoflex.com to get a full understanding of this exciting new opportunity.”

ImmunoFlex CEO Chris Wagner stated, “ImmunoFlex works with the immune system to prevent and combat disease. We started with a shared interest in understanding the immune system and how different compounds have the potential to strengthen, support, and enhance our bodies natural surveillance system. Our research led us to form ImmunoFlex, where we develop and commercialize novel patented products that counteract weakened immune systems and diminished immune repertoire caused by a lifetime of battling viruses and disease. We are using genomics and other modern scientific tools to repurpose existing natural health products and studying their ability to enhance the human immune system and its capacity to prevent and combat viral infections. Our first product launch, targeted for late 2020, is pharmaceutical grade and designed to improve adaptive immunity biomarkers. We believe this product will become especially important for researchers, clinical users, and people interested in enhancing their immune system’s ability to respond to new threats. Chemistree’s support of ImmunoFlex is a strong signal from professional investors who believe we can improve the health of a large group of people.”

Chemistree’s investment in ImmunoFlex is subject to confirmatory due diligence and the completion of a definitive investment agreement. The investment includes an initial common share purchase of $500,000, together with Chemistree being granted a gross sales royalty on ImmunoFlex’s North American sales; a further $500,000 second tranche common share purchase is conditional on certain performance by ImmunoFlex. In addition, Chemistree is entitled to anti-dilution pre-emptive rights and to appoint one person to ImmunoFlex’s board of directors.

About Chemistree Technology Inc.
Chemistree Technology Inc. is an investment company dedicated to the U.S. cannabis sector, endeavoring to provide turn-key solutions for the regulated cannabis industry. The Company’s corporate strategy is to acquire and develop vertically integrated cannabis assets and to invest in other cannabis-related opportunities, leveraging management’s decades of expertise in the cannabis industry and corporate finance.

For more information, visit www.Chemistree.ca.

Advisory
The Company wishes to inform shareholders that there are significant legal restrictions and regulations that govern the cannabis industry in both Canada and the United States.

Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws
The concepts of “medical cannabis” and “recreational cannabis” do not exist under U.S. federal law. The Federal Controlled Substances Act classifies “marihuana” as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defence to any federal proceeding which may be brought against the Company. Enforcement of U.S. federal laws will be a significant risk to the business of the Company and any such proceedings brought against the Company may adversely affect the Company’s operations and financial performance.

Further information regarding the legal status of cannabis related activities and associated risk factors, including, but not limited to, risk of enforcement actions, risks that third-party service providers, such as banking or financial institutions cease providing services to the Company, and the risk that Company may not be able to distribute profits, if any, from U.S. operations up to the Company, are included in the Prospectus, the Company’s annual information form and other documents incorporated by reference therein and in the Company’s Form 2A listing statement filed with the CSE and available under the Company’s profile on SEDAR at www.sedar.com.

“Karl Kottmeier”
President 

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Information set forth in this news release includes forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, “budget”, “scheduled” and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein, without limitation, statements with respect to the investment and grant of a royalty interest, and entry into of definitive agreements.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the Company’s reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made, and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

SOURCE Chemistree Technology Inc.

For further information: Chemistree Technology Inc., Karl Kottmeier, President, Phone: 604-678-8941, Email: [email protected]; For investor relations please contact: Contact Financial Corp., Kirk Gamley, Phone: 604-689-7422, Email: [email protected]

Related Links

http://chemistree.ca/

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Investment

Amazon completes $4B Anthropic investment to advance generative AI – About Amazon

Published

 on

By


Amazon concludes $4 billion investment in Anthropic.

Customers of all sizes and industries are using Claude on Amazon Bedrock to reimagine user experiences, reinvent their businesses, and accelerate their generative AI journeys.

300x250x1

The work Amazon and Anthropic are doing together to bring the most advanced generative artificial intelligence (generative AI) technologies to customers worldwide is only beginning. As part of a strategic collaborative agreement, we and Anthropic announced that Anthropic is using Amazon Web Services (AWS) as its primary cloud provider for mission critical workloads, including safety research and future foundation model development. Anthropic will use AWS Trainium and Inferentia chips to build, train, and deploy its future models and has made a long-term commitment to provide AWS customers around the world with access to future generations of its foundation models on Amazon Bedrock, AWS’s fully managed service that provides secure, easy access to the industry’s widest choice of high-performing, fully managed foundation models (FMs), along with the most compelling set of features (including best-in-class retrieval augmented generation, guardrails, model evaluation, and AI-powered agents) that help customers build highly-capable, cost-effective, low latency generative AI applications.

Earlier this month, we announced access to the most powerful Anthropic AI models on Amazon Bedrock. The Claude 3 family of models demonstrate advanced intelligence, near-human levels of responsiveness, improved steerability and accuracy, and new vision capabilities. Industry benchmarks show that Claude 3 Opus, the most intelligent of the model family, has set a new standard, outperforming other models available today—including OpenAI’s GPT-4—in the areas of reasoning, math, and coding.

“We have a notable history with Anthropic, together helping organizations of all sizes around the world to deploy advanced generative artificial intelligence applications across their organizations,” said Dr. Swami Sivasubramanian, vice president of Data and AI at AWS. “Anthropic’s visionary work with generative AI, most recently the introduction of its state-of-the art Claude 3 family of models, combined with Amazon’s best-in-class infrastructure like AWS Tranium and managed services like Amazon Bedrock further unlocks exciting opportunities for customers to quickly, securely, and responsibly innovate with generative AI. Generative AI is poised to be the most transformational technology of our time, and we believe our strategic collaboration with Anthropic will further improve our customers’ experiences, and look forward to what’s next.”

Global organizations of all sizes, across virtually every industry, are already using Amazon Bedrock to build their generative AI applications with Anthropic’s Claude AI. They include ADP, Amdocs, Bridgewater Associates, Broadridge, CelcomDigi, Clariant, Cloudera, Dana-Farber Cancer Institute, Degas Ltd., Delta Air Lines, Druva, Enverus, Genesys, Genomics England, GoDaddy, Happy Fox, Intuit, KT, LivTech, Lonely Planet, LexisNexis Legal & Professional, M1 Finance, Netsmart, Nexxiot, Parsyl, Perplexity AI, Pfizer, the PGA TOUR, Proto Hologram, Ricoh USA, Rocket Companies, and Siemens.

To further help speed the adoption of advanced generative AI technologies, AWS, Anthropic, and Accenture recently announced that they are coming together to help organizations—especially those in highly-regulated industries including healthcare, public sector, banking, and insurance—responsibly adopt and scale generative AI solutions. Through this collaboration, organizations will gain access to best-in-class models from Anthropic, a broad set of capabilities only available on Amazon Bedrock, and industry expertise from Accenture, Anthropic, and AWS to help them build and scale generative AI applications that are customized for their specific use cases.

Deepening our commitment to advancing generative AI, today we have an update on the announcement we made to invest up to $4 billion in Anthropic for a minority ownership position in the company. Last September, we made an initial investment of $1.25 billion. Today, we made our additional $2.75 billion investment, bringing our total investment in Anthropic to $4 billion. To learn more about the broader strategic collaboration between Amazon and Anthropic, of which this investment is one part, check out the stories below:

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Investment

Amazon doubles down on Anthropic, completing its planned $4B investment – TechCrunch

Published

 on

By


Amazon invested a further $2.75 billion in growing AI power Anthropic on Wednesday, following through on the option it left open last September. The $1.25 billion it invested at the time must be producing results, or perhaps they’ve realized that there are no other horses available to back.

The September deal put $1.25 billion into the company in exchange for a minority stake, and certain tit-for-tat agreements like Anthropic continuing to use AWS for its extensive computation needs.

Amazon reportedly had until the end of the first quarter to decide whether to increase its investment to a maximum of $4 billion, and here we are just before the deadline, and the company has decided to throw in the maximum amount.

300x250x1

Anthropic’s AI models are one of very few that compete at the highest levels of capability (however you define it) yet are available at scale for enterprises to deploy internally or in user-facing applications. OpenAI’s GPT series and Google’s Gemini are the others up there, but upstarts like Mistral may soon threaten that fragile triumvirate.

Lacking the capability to develop adequate models on their own for whatever reason, companies like Amazon and Microsoft have had to act vicariously through others, primarily OpenAI and Anthropic. The two have reaped immense benefits by allying with one or the other of these moneyed rivals, and as yet have not seen many downsides.

What we can take from Amazon’s decision to invest the maximum after (one must assume) getting a pretty close look at how they make the AI sausage over there is, really, pretty scant.

It makes too much strategic sense for these companies, which possess enormous war chests saved up for exactly this purpose (outspending rivals when they can’t out-innovate them), to pour cash into the AI sector. Right now the AI world is a bit like a roulette table, with OpenAI and Anthropic representing black and red. No one really knows where the ball will land, least of all the companies that couldn’t predict or create this technology themselves. But if your bitter enemy puts their chips down on red, it only makes sense for you to bet on black.

Especially if you can bet on black at a discount — which is what Amazon got here, since it could invest at Anthropic’s September valuation, which is most certainly lower than it is today.

That said, if things were looking sketchy over there — the way they must have looked at Inflection before Microsoft pounced on it — Amazon could have backed out or just invested less than the full supplemental $2.75 billion. But that might have sent a confusing signal no one wants getting out there, least of all existing multibillion-dollar investors.

We know Anthropic has a plan, and this year we’ll find out what Amazon, Apple, Microsoft and other multinational interests think they can do to monetize this supposedly revolutionary technology.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Investment

Canada to tighten foreign investment rules for AI, other sectors

Published

 on

Canada will require foreign companies to warn the government in advance before making investments or acquisitions in artificial intelligence, quantum computing and space technology, Bloomberg News reported on Tuesday, citing an interview with Innovation Minister Francois-Philippe Champagne.

The move will aid the government in conducting a national-security review before transactions get too far advanced and would-be investors may be restricted in their access to target companies’ user data or other property while the inquiry is taking place, the report said.


Click to play video: 'Canadians concerned about risk of AI generated fraud'
4:47
Canadians concerned about risk of AI generated fraud

300x250x1

 


The tougher rules will also apply to investments in critical minerals and potentially other sectors, Champagne said to Bloomberg.

Earlier this month, Champagne said Canada will crack down on foreign investment in the interactive digital media sector to stop state-sponsored actors from endangering national security.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Trending